Therapeutics Solution International announced the filing of a patent application covering novel findings demonstrating enhancement of blood brain barrier integrity subsequent to traumatic brain injury.
Celltex Therapeutics has initiated talks with the US Food and Drug Administration (FDA) to conduct a study of adult, autologous mesenchymal stem cells (MSCs) for the treatment of Covid-19 symptoms.